Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

593
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
593
Amyloid Fibrils03:03

Amyloid Fibrils

11.2K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.2K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

2.3K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.2K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Taming the "death receptor": translating the first-in-class p75<sup>NTR</sup> modulator LM11A-31 from basic biology, across broad preclinical models, to clinical proof-of-concept.

Journal of translational medicine·2026
Same author

Status and key determinants of integrated farming systems in coastal regions of eastern India: a comparative assessment.

Scientific reports·2026
Same author

Green extraction techniques and advanced coating technologies for development of edible film valorizing fruit and vegetables peels.

Journal of food science and technology·2026
Same author

Correction to: Green extraction techniques and advanced coating technologies for development of edible film valorizing fruit and vegetables peels.

Journal of food science and technology·2026
Same author

Preformed fibrils of α-synuclein rapidly activate LRRK2 on early endosomes, driving Rab5 phosphorylation and disrupting endolysosomal and synaptic function.

NPJ Parkinson's disease·2026
Same author

Unveiling the potential of banana (<i>Musa</i> spp.) improvement through genetic manipulation: current trends and future implications.

Plant signaling & behavior·2026

Related Experiment Video

Updated: Nov 26, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K

Cholesterol-lowering drugs reduce APP processing to Aβ by inducing APP dimerization.

Vanessa F Langness1,2, Rik van der Kant3,4, Utpal Das5,2

  • 1Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093.

Molecular Biology of the Cell
|December 9, 2020
PubMed
Summary

Statins effectively reduce amyloid beta (Aβ) in human neurons by altering cholesterol metabolism. This mechanism involves decreasing the interaction between amyloid precursor protein (APP) and BACE1, thereby lowering Aβ production in Alzheimer

More Related Videos

Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain
10:08

Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain

Published on: August 28, 2012

12.1K
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
07:55

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

12.1K

Related Experiment Videos

Last Updated: Nov 26, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K
Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain
10:08

Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain

Published on: August 28, 2012

12.1K
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
07:55

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

12.1K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Amyloid beta (Aβ) plaques are a hallmark of Alzheimer's disease (AD).
  • Cholesterol metabolism's role in amyloid precursor protein (APP) processing to Aβ is not fully understood.
  • Statins are known to affect cholesterol metabolism.

Purpose of the Study:

  • To elucidate the mechanism by which altering cholesterol metabolism influences APP processing.
  • To investigate the effect of statins on Aβ production in human neurons.

Main Methods:

  • Utilized induced pluripotent stem cell (iPSC)-derived neurons.
  • Employed bimolecular fluorescence complementation (BiFC) assays in transfected cells.
  • Analyzed APP processing, APP-BACE1 interaction, and APP dimerization.

Main Results:

  • Statins decreased Aβ generation and sAPPβ levels.
  • Statins increased full-length APP (flAPP) levels, indicating reduced BACE1 processing.
  • Statins reduced flAPP interaction with BACE1 and enhanced APP dimerization, dependent on cholesterol binding to APP.

Conclusions:

  • Statins reduce Aβ production by decreasing BACE1 interaction with flAPP.
  • APP dimerization and APP cholesterol binding may compete, regulating Aβ production.
  • Findings suggest a novel mechanism for statin action in AD pathology.